Business Context and Reporting Period
This Form 8-K was filed by Mangoceuticals, Inc. on August 4, 2026. The Company is incorporated in Texas and its common stock (Ticker: MGRX) trades on the Nasdaq Capital Market. The filing addresses a listing deficiency regarding the minimum bid price requirement and provides an update on a pending business combination.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status and corporate events.
Material Changes and Events
- Nasdaq Compliance Extension: The Company received a "Second Notice" from Nasdaq granting an additional 180-day compliance period (until February 1, 2027) to regain compliance with the minimum bid price requirement (Rule 5550(a)(2)).
- Deficiency Details: The initial deficiency was triggered because the stock closed below $1.00 per share for 30 consecutive business days starting February 4, 2026.
- Eligibility Criteria: The extension was granted because the Company meets all other initial listing requirements, including the market value of publicly held shares.
- Proposed Cure: The Company intends to cure the deficiency during the new compliance period by effecting a reverse stock split, if necessary.
- Business Combination: The Company recently announced an entrance into a business combination agreement with Nuclea Energy Inc.
Outlook, Risks, and Management Commentary
Management stated that the Second Notice has no immediate effect on the listing or trading of the Company's common stock. The Company intends to actively monitor the closing bid price and take all necessary actions to resolve the deficiency. The filing references a press release (Exhibit 99.1) containing further commentary on the Nuclea Energy business combination.
Investor Verification Checklist
- Verify the current trading price of MGRX to assess the likelihood of meeting the $1.00 bid price requirement without a reverse split.
- Review the terms of the business combination agreement with Nuclea Energy Inc. for potential dilution or strategic shifts.
- Monitor future filings for the formal proposal and shareholder approval of a reverse stock split.
- Confirm the Company's continued compliance with other Nasdaq listing requirements (e.g., market value of publicly held shares) throughout the extension period.